JP2020534865A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534865A5 JP2020534865A5 JP2020531567A JP2020531567A JP2020534865A5 JP 2020534865 A5 JP2020534865 A5 JP 2020534865A5 JP 2020531567 A JP2020531567 A JP 2020531567A JP 2020531567 A JP2020531567 A JP 2020531567A JP 2020534865 A5 JP2020534865 A5 JP 2020534865A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- subject
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762547220P | 2017-08-18 | 2017-08-18 | |
| US62/547,220 | 2017-08-18 | ||
| US201762611166P | 2017-12-28 | 2017-12-28 | |
| US62/611,166 | 2017-12-28 | ||
| PCT/US2018/047084 WO2019036719A2 (en) | 2017-08-18 | 2018-08-20 | GENETICALLY MODIFIED DNASE ENZYMES AND THEIR USE IN THERAPY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534865A JP2020534865A (ja) | 2020-12-03 |
| JP2020534865A5 true JP2020534865A5 (https=) | 2021-09-30 |
| JP7577314B2 JP7577314B2 (ja) | 2024-11-05 |
Family
ID=65362608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531567A Active JP7577314B2 (ja) | 2017-08-18 | 2018-08-20 | 改変型ｄｎａｓｅ酵素及び治療における使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10696956B2 (https=) |
| EP (2) | EP3668972B8 (https=) |
| JP (1) | JP7577314B2 (https=) |
| KR (2) | KR20250073498A (https=) |
| CN (1) | CN111566207A (https=) |
| AU (1) | AU2018318313B2 (https=) |
| BR (1) | BR112020003403A2 (https=) |
| CA (1) | CA3073317A1 (https=) |
| DK (1) | DK3668972T3 (https=) |
| ES (1) | ES3008982T3 (https=) |
| IL (2) | IL272715B2 (https=) |
| MX (1) | MX2020001913A (https=) |
| SG (1) | SG11202001445XA (https=) |
| UA (1) | UA129696C2 (https=) |
| WO (1) | WO2019036719A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246905B2 (en) | 2016-08-15 | 2022-02-15 | President And Fellows Of Harvard College | Treating infections using IdsD from Proteus mirabilis |
| EP3351263A1 (en) * | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| DK3668972T3 (da) | 2017-08-18 | 2025-01-13 | Neutrolis Inc | Konstruerede dnase-enzymer og anvendelse i terapi |
| AU2019209770B2 (en) | 2018-01-16 | 2025-07-31 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
| US11058724B2 (en) | 2018-10-08 | 2021-07-13 | Neutrolis, Inc. | Methods of using DNASE1-like 3 in therapy |
| IL325846A (en) * | 2018-10-08 | 2026-03-01 | Neutrolis Inc | Engineering deoxyribonuclease enzymes for manufacturing and medicine |
| US10988746B2 (en) | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
| WO2020163264A1 (en) * | 2019-02-04 | 2020-08-13 | Neutrolis, Inc. | Engineered human extracellular dnase enzymes for drug candidate selection |
| US11352613B2 (en) | 2019-02-04 | 2022-06-07 | Neutrolis, Inc. | Engineered human extracellular DNASE enzymes |
| WO2020227415A1 (en) * | 2019-05-06 | 2020-11-12 | President And Fellows Of Harvard College | Dna-degrading proteins and uses thereof |
| WO2021071733A1 (en) * | 2019-10-07 | 2021-04-15 | Texas Tech University System | Mutant dnase1l3 with improved serum half-life |
| IL294114A (en) * | 2020-01-11 | 2022-08-01 | Univ Yale | Preparations and methods for the treatment, improvement and/or prevention of diseases or disorders caused by or related to dnase1 and/or dnase1l3 |
| WO2021168413A1 (en) * | 2020-02-20 | 2021-08-26 | Neutrolis, Inc. | Basic domain-deleted dnase1-like 3 and uses thereof |
| US20230174944A1 (en) * | 2020-04-15 | 2023-06-08 | Cartesian Therapeutics, Inc. | Engineered cells secreting therapeutic enzymes |
| US20230226138A1 (en) * | 2020-06-01 | 2023-07-20 | Black Cat Bio Limited | Compositions and methods for treating infections and netopathy |
| EP4161645A4 (en) * | 2020-06-08 | 2023-11-01 | Yale University | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING COAGULOPATHY AND/OR SEPSIS IN PATIENTS WITH BACTERIAL AND/OR VIRAL INFECTIONS |
| EP4225903A1 (en) | 2020-10-07 | 2023-08-16 | Protalix Ltd. | Long-acting dnase |
| WO2025076525A1 (en) * | 2023-10-06 | 2025-04-10 | Neutrolis, Inc. | Biomarker and precision therapy for inflammatory disease |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6270989B1 (en) * | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US6348343B2 (en) | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
| US6482626B2 (en) | 1996-02-05 | 2002-11-19 | Genentech, Inc. | Human DNase |
| US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| US6656685B2 (en) | 2001-01-29 | 2003-12-02 | Ventana Medical Systems, Inc. | Hybridization buffers using low molecular weight dextran sulfate and methods for their use |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| US20040138156A1 (en) | 2002-02-26 | 2004-07-15 | Schneider Michael C | Therapeutic regulation of deoxyribonuclease-1-like-3 activity |
| US9248166B2 (en) | 2003-07-14 | 2016-02-02 | Cls Therapeutics Limited | Method for treating oncological diseases |
| WO2006130034A1 (fr) | 2005-04-25 | 2006-12-07 | Dmitry Dmitrievich Genkin | Procede pour prolonger la duree de vie d'animaux ou de l'humain |
| US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
| RU2269356C2 (ru) | 2003-07-14 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ лечения онкологических заболеваний |
| US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| EP2416156B1 (en) | 2006-10-18 | 2015-12-30 | Periness Ltd. | Method for determining a male fertility status |
| US20090305345A1 (en) | 2006-10-23 | 2009-12-10 | Medical Research Council | Polymerase |
| AU2008279550B2 (en) * | 2007-06-21 | 2012-08-09 | Angelica Therapeutics, Inc. | Modified toxins |
| MX341084B (es) * | 2009-11-02 | 2016-08-05 | Univ Washington | Composiciones de nucleasas terapéuticas y métodos. |
| EP2561367A1 (en) | 2010-04-22 | 2013-02-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations |
| CN107188970A (zh) | 2010-06-04 | 2017-09-22 | 株式会社蒂奥姆生物 | 具有因子vii活性的融合蛋白质 |
| WO2012106264A2 (en) | 2011-01-31 | 2012-08-09 | The Trustees Of Columbia University In The City Of New York | Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections |
| WO2012166611A2 (en) | 2011-05-27 | 2012-12-06 | Immune Disease Institute, Inc. | Methods for treating and preventing neutrophil-derived net toxicity and thrombosis |
| US9867871B2 (en) | 2011-12-12 | 2018-01-16 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating nucleic acid-related eye disease |
| GB201208879D0 (en) | 2012-05-21 | 2012-07-04 | London School Hygiene & Tropical Medicine | Therapeutic for treating Clostridium difficile infection |
| HRP20192080T1 (hr) | 2013-10-31 | 2020-02-07 | Resolve Therapeutics, Llc | Terapeutske fuzije nukleaza-albumine i postupci |
| CA2935748A1 (en) * | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| CN107249621A (zh) | 2014-09-08 | 2017-10-13 | 哥谭生物制药股份有限公司 | 用于治疗肺结节病的粘液溶解剂 |
| WO2016118476A1 (en) | 2015-01-20 | 2016-07-28 | The Children's Medical Center Corporation | Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing |
| EP3265814B1 (en) | 2015-03-01 | 2020-11-18 | Immunarray Ltd. | Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens |
| EP3273238A1 (en) | 2016-07-22 | 2018-01-24 | Universitätsklinikum Hamburg-Eppendorf | Immunodiagnostic detection of anti-neutrophil antibodies |
| CA3036926C (en) | 2016-09-30 | 2022-05-31 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| EP3570667B1 (en) | 2017-01-20 | 2022-11-16 | Neutrolis Inc. | Animal model for drug development |
| DK3668972T3 (da) | 2017-08-18 | 2025-01-13 | Neutrolis Inc | Konstruerede dnase-enzymer og anvendelse i terapi |
-
2018
- 2018-08-20 DK DK18846060.4T patent/DK3668972T3/da active
- 2018-08-20 KR KR1020257014953A patent/KR20250073498A/ko active Pending
- 2018-08-20 SG SG11202001445XA patent/SG11202001445XA/en unknown
- 2018-08-20 CN CN201880068103.8A patent/CN111566207A/zh active Pending
- 2018-08-20 IL IL272715A patent/IL272715B2/en unknown
- 2018-08-20 KR KR1020207007703A patent/KR102806169B1/ko active Active
- 2018-08-20 EP EP18846060.4A patent/EP3668972B8/en active Active
- 2018-08-20 BR BR112020003403-7A patent/BR112020003403A2/pt unknown
- 2018-08-20 EP EP24205258.7A patent/EP4509135A3/en active Pending
- 2018-08-20 AU AU2018318313A patent/AU2018318313B2/en active Active
- 2018-08-20 WO PCT/US2018/047084 patent/WO2019036719A2/en not_active Ceased
- 2018-08-20 CA CA3073317A patent/CA3073317A1/en active Pending
- 2018-08-20 UA UAA202001869A patent/UA129696C2/uk unknown
- 2018-08-20 IL IL317968A patent/IL317968A/en unknown
- 2018-08-20 MX MX2020001913A patent/MX2020001913A/es unknown
- 2018-08-20 ES ES18846060T patent/ES3008982T3/es active Active
- 2018-08-20 JP JP2020531567A patent/JP7577314B2/ja active Active
-
2019
- 2019-08-02 US US16/530,141 patent/US10696956B2/en active Active
-
2020
- 2020-07-15 US US16/929,980 patent/US10801019B1/en active Active
- 2020-09-11 US US17/018,642 patent/US11046942B2/en active Active
- 2020-10-12 US US17/068,105 patent/US11046943B2/en active Active
-
2021
- 2021-03-05 US US17/193,455 patent/US20210277372A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534865A5 (https=) | ||
| Tsung et al. | High‐mobility group box‐1 in sterile inflammation | |
| Dimberg | Chemokines in angiogenesis | |
| Kozar et al. | Syndecan-1 restitution by plasma after hemorrhagic shock | |
| Koenen et al. | Chemokines: established and novel targets in atherosclerosis | |
| Vlahos et al. | Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophage-colony stimulating factor (GM-CSF) | |
| Bucala et al. | The integral role of CD74 in antigen presentation, MIF signal transduction, and B cell survival and homeostasis | |
| CA2863862C (en) | Polypeptides binding to human complement c5 | |
| Tsou et al. | Harnessing CXCR4 antagonists in stem cell mobilization, HIV infection, ischemic diseases, and oncology | |
| de Oliveira et al. | Tissue dependent role of PTX3 during ischemia-reperfusion injury | |
| Liao et al. | Neutrophil-derived IL-17 promotes ventilator-induced lung injury via p38 MAPK/MCP-1 pathway activation | |
| JP2013107899A5 (https=) | ||
| JP5462623B2 (ja) | Ｅｌｒ−ｃｘｃケモカインの高親和性アンタゴニスト | |
| JP2024160327A (ja) | 製造及び治療のためのｄｎａｓｅ酵素の操作 | |
| JP2016535062A (ja) | 特異的補体系を標的化する阻害剤ならびにその調製方法および使用 | |
| CN106565836A (zh) | 高亲和力的可溶性pdl-1 分子 | |
| JP2017537888A5 (https=) | ||
| Hermert et al. | The nucleic acid binding protein YB-1–controlled expression of CXCL-1 modulates kidney damage in liver fibrosis | |
| JP2020019813A5 (https=) | ||
| Barnum | Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease | |
| CA3172548A1 (en) | Basic domain-deleted dnase1-like 3 and uses thereof | |
| Vogel et al. | Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases | |
| Zhao et al. | A novel accessory molecule Trim59 involved in cytotoxicity of BCG-activated macrophages | |
| Brilland et al. | Anti-pentraxin antibodies in autoimmune diseases: bystanders or pathophysiological actors? | |
| Khan et al. | Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective |